| Name | Title | Contact Details |
|---|---|---|
Ray Gerena |
US Vice President of Sales | Profile |
Jon Hyink |
Service Sales Director | Profile |
Derek Olender |
Vice President, Head of Enterprise Product Definition | Profile |
Keith Chrzanowski |
Director of Human Resources | Profile |
Cameron Conneely |
Director - Global Learning and Development | Profile |
Canon U.S. Life Sciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
IOMED is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 1981, Atrium is a diversified healthcare provider where improved patient outcomes is job one for every member of the firm. From Hudson, NH to Mosman (Sydney), Australia or Mijdrecht, The Netherlands, service and workmanship in the quality
Sovereign Medical Services (SMS “The Company” is a leader in the fast-growing Medical Ancillary Services within the health care industry. SMS provides the health care professional: management expertise, and investment opportunities in multiple Medical Surgical services. It also provides expertise in managing primary care and multi-specialty practices, with the State of Art information technology systems. These ancillaries are high quality, profitable, cost effective services.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.